MedscapeTop News From ACR 2013: SlideshowMedscapeRituximab (Rituxan, Genentech) is a potential treatment option in immunoglobulin G4-related disease (IgG4), say researchers reporting first evidence. Lead investigator John Stone, MD, from Massachusetts …
MedscapeNew CLL Drug Delays Disease by Nearly 1 YearMedscapeObinutuzumab, which is indicated for use in combination with chlorambucil for patients with previously untreated CLL, improved median progression-free survival by nearly a year more than ritux…
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
Fort Mills Times Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
Business Wire (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
4-traders (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
|
Potential Utility of Rituximab for Graves’ Orbitopathy
Journal of Clinical Endocrinology and Metabolism Address all correspondence and requests for reprints to: Mario Salvi, MD, Graves’ Orbitopathy Unit, Fondazione Cà Granda, Istituto di Ricovero e Cura a Carattere Scientifico, Department of Clinical and Community Sciences, University of Milan, Via … |
|
First Proof for Rituximab in IgG4-Related Disease
Medscape SAN DIEGO — Rituximab (Rituxan, Genentech) is a potential treatment option in the multiorgan fibroinflammatory disorder known as immunoglobulin G4-related disease (IgG4), according to researchers reporting first evidence. “New therapeutic strategies … |
OncLiveFDA Approves Frontline Obinutuzumab for CLLOncLiveIn the three-arm study, patients were randomized in a 1:2:2 ratio to receive six cycles every 28 days of chlorambucil (n = 118), chlorambucil plus obinutuzumab (n = 238), or chlorambucil plus rit…
|
Efficacy and safety of rituximab treatment in early primary Sjogren’s syndrome …
7thSpace Interactive (press release) IntroductionPrimary Sjogren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands and characterized, in most cases, by a rather mild clinical picture. However, a subgroup of pSS patients experience systemic extra-glandular involvement … |
Rituximab and abatacept but not tocilizumab impair antibody response to …7thSpace Interactive (press release)IntroductionThe objective of the study was to investigate the impact of newer biologic treatments including rituximab, abatacept and tocilizu…